Business Wire

  1. NextPoint Therapeutics Announces Clinical Entry Of NPX372, A First-In-Class B7-H7–Targeted T Cell Engager To Treat Solid Tumors 2/9/2026

    NextPoint Therapeutics, a clinical-stage biotechnology company developing a new world of precision therapeutics through its leading scientific work on the novel B7-H7 axis, today announced the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate clinical development of NPX372, a first-in-class T cell engager (TCE) for the treatment of patients with solid tumors.

  2. Iambic Announces Collaboration With Takeda To Advance AI-Driven Design Of Small Molecules 2/9/2026

    Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced a multi-year technology and discovery collaboration agreement with Takeda that will use Iambic’s industry leading AI drug discovery models to advance a select set of high-priority small molecule programs, initially in Takeda’s Oncology and Gastrointestinal and Inflammation therapeutic areas.

  3. BioSelective Capital Investments Completes Acquisition Of BioDuro's Irvine, California Drug Product Development And Manufacturing Operations 2/4/2026

    BioSelective Capital Investments and Shayan Enterprises, LLC, a Utah-based risk-capital investment firm, today announced the successful acquisition of BioDuro’s drug product development and manufacturing operations in Irvine, California, resulting in the formation of Forma Life Sciences, Inc. (FORMA), a Delaware corporation established to hold and operate the acquired assets.

  4. Zonsen PepLib Biotech Enters Global R&D Collaboration And License Agreement With Lilly 2/3/2026

    Zonsen PepLib Biotech Inc. (“PepLib”) today announced that it has entered a global research and development (R&D) collaboration and license agreement with Eli Lilly and Company ("Lilly").

  5. Exelixis Announces U.S. FDA Accepted The New Drug Application For Zanzalintinib In Combination With An Immune Checkpoint Inhibitor For Patients With Metastatic Colorectal Cancer 2/2/2026

    Exelixis, Inc. today announced that its New Drug Application (NDA) for zanzalintinib, in combination with atezolizumab (Tecentriq), has been accepted for review in the U.S. for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, and, if RAS wild-type, an anti-epidermal growth factor receptor (EGFR) therapy. The Food and Drug Administration (FDA) assigned a standard review with a Prescription Drug User Fee Act target action date of December 3, 2026.

  6. Onchilles Pharma Announces IND Clearance For N17350, Advancing The First Next-Generation Cytotoxic Therapeutic Leveraging The ELANE Pathway Into The Clinic 2/2/2026

    Onchilles Pharma, a private biotech company pioneering next-generation cytotoxic therapeutics that harness the ELANE pathway, today announced the U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for N17350 to initiate first-in-human clinical studies in patients with advanced solid tumors.

  7. Unravel Biosciences And The SCN2A Foundation Announce Drug Discovery Collaboration 1/28/2026

    The SCN2A Foundation today announced a research collaboration with Unravel Biosciences, Inc., an AI-enabled therapeutics company established to advance drugs for complex diseases.

  8. Drug Farm Announces FDA Fast Track Designation For First-In-Class ALPK1 Inhibitor DF-003 For The Treatment Of ROSAH Syndrome 1/27/2026

    Drug Farm, a clinical-stage biopharmaceutical company advancing two novel small molecule drugs for ROSAH syndrome and hepatitis B, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to DF-003, its investigational, first-in-class ALPK1 inhibitor, for the treatment of ROSAH syndrome, a rare, autosomal dominant autoinflammatory disease with no approved therapies.

  9. Novaliq Receives FDA IND Clearance To Advance NOV05 In A Phase II Clinical Trial In Non-Infectious Anterior Uveitis 1/26/2026

    Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique water-free EyeSol drug category, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for NOV05, the company’s first IND for treating inner-eye diseases.

  10. Ellipses In-Licenses First-In-Class B7H3 Antibody Drug Conjugate From China 1/22/2026

    Ellipses Pharma Limited (“Ellipses”), a clinical-stage oncology drug development company with a pipeline of innovative programmes, announced that it has entered into a collaboration and licence agreement with Innolake Biopharm Co. Ltd (“Innolake”) to develop a clinical stage first-in-class antibody drug conjugate (ADC).